Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $992K fell 61.8% year over year, behind the -39.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 53.4% from the prior quarter. Over 3 fiscal years it compounded at -34.0% a year.
Context
- Stock-based compensation amounted to 23.0% of revenue in FY2025, up 1.5 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -61.8% toward the trailing-twelve-month pace of -39.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.08M USD
- Year-over-year change
- -26.7%
- 4-year CAGR
- -27.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.08M | -26.7% |
| FY2024 | 2024-12-31 | 12.38M | -54.7% |
| FY2023 | 2023-12-31 | 27.36M | -13.5% |
| FY2022 | 2022-12-31 | 31.65M | -4.0% |
| FY2021 | 2021-12-31 | 32.96M | — |
Stock-Based Compensation vs competitors
How SGMO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -39.0% is the 9th highest of 11, against a peer median of -16.1%.
- Stock-based compensation amounts to 21.6% of revenue for SGMO, versus a peer median of 98.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.26M USD | -43.8% | -14.0% | 46.7% | |
| LTM Mar 2026 | $15.02M USD | -24.7% | -4.8% | 52.0% | |
| LTM Mar 2026 | $11.51M USD | -33.2% | -18.7% | 20.6% | |
| LTM Mar 2026 | $8.67M USD | -29.5% | -12.8% | 11.1% | |
| LTM Mar 2026 | $7.48M USD | -39.0% | -34.0% | 21.6% | |
| LTM Mar 2026 | $6.67M USD | -45.2% | -9.2% | 210.3% | |
| LTM Mar 2026 | $6.14M USD | +9.4% | -6.2% | 344.3% | |
| FY2025 | €4.26M EUR | +7.9% | +0.1% | 152.7% | |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
| LTM Mar 2026 | $2.9M USD | -7.5% | -5.6% | 98.2% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.4M USD | +50.7% | -39.5% | 123.1% |
| Peer median (excluding SGMO) | — | -16.1% | -7.7% | 98.2% | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (178.3M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Depreciation & Amortization | 17.64M | 20.56M | 22.19M | 9.36M | 7.6M |
| Deferred Income Tax | 2.77M | 0 | (6.34M) | 0 | 0 |
| Stock-Based Compensation | 32.96M | 31.65M | 27.36M | 12.38M | 9.08M |
| Change in Working Capital | (101.9M) | (82.32M) | (164.03M) | 4.51M | (4.22M) |
| Accounts Receivables | (789K) | 2.34M | (976K) | 953K | 155K |
| Inventory | 7.66M | 0 | 0 | 0 | 0 |
| Accounts Payables | (7.66M) | 13.35M | 5.59M | (14.17M) | 2.79M |
| Other Working Capital | (101.11M) | (98M) | (168.65M) | 17.72M | (7.17M) |
| Other Non-Cash Items | (6.43M) | (1.24M) | 153.8M | 4.55M | 13.27M |
| Operating Cash Flow | (233.25M) | (223.63M) | (224.84M) | (67.14M) | (97.21M) |
| Capital Expenditures | (23.28M) | (20.17M) | (21.16M) | (267K) | (102K) |
| Acquisitions (Net) | (119K) | (79.46M) | 0 | 1.95M | 0 |
| Purchases of Investments | (338.16M) | (277.39M) | (59.55M) | 0 | 0 |
| Sales of Investments | 609.76M | 356.85M | 234.24M | 35.84M | 0 |
| Other Investing Activities | 0 | 79.46M | 0 | 0 | 0 |
| Investing Cash Flow | 248.2M | 59.29M | 153.53M | 37.52M | (102K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 27.1M | 84.87M | 15.11M | 28.99M | 74.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.76M | (209K) | (518K) | (614K) | (3.26M) |
| Financing Cash Flow | 32.86M | 84.66M | 14.59M | 28.38M | 70.75M |
| Effect of Forex Changes | (263K) | 1.25M | 1.48M | (2.05M) | 4.09M |
| Net Change in Cash | 47.54M | (78.43M) | (55.24M) | (3.29M) | (22.47M) |
| Free Cash Flow | (256.53M) | (243.8M) | (246M) | (67.41M) | (97.31M) |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.